SWX:AGFB

Stock Analysis Report

Executive Summary

Agfa-Gevaert NV develops, produces, and distributes various analog and digital imaging systems, and IT solutions worldwide.

Snowflake

Fundamentals

Moderate growth potential and overvalued.

Risks

  • Agfa-Gevaert is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Agfa-Gevaert's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

SWX:AGFB

3.0%

CH Healthcare Services

0.4%

CH Market


1 Year Return

-6.4%

SWX:AGFB

-8.3%

CH Healthcare Services

2.3%

CH Market

AGFB outperformed the Healthcare Services industry which returned -8% over the past year.

AGFB underperformed the Market in Switzerland which returned 2.3% over the past year.


Share holder returns

AGFBIndustryMarket
7 Day0%3.0%0.4%
30 Day0%-11.1%-1.2%
90 Day-4.6%-10.6%1.0%
1 Year-6.4%-6.4%-7.2%-8.3%7.6%2.3%
3 Year13.9%13.9%17.3%12.6%29.6%13.2%
5 Yearn/a101.8%87.7%32.1%11.6%

Price Volatility Vs. Market

How volatile is Agfa-Gevaert's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Agfa-Gevaert undervalued based on future cash flows and its price relative to the stock market?

2.51x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Agfa-Gevaert to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Agfa-Gevaert to establish if it is available at substantial discount.


Price Based on Earnings

Agfa-Gevaert is loss making, we can't compare its value to the Europe Healthcare Services industry average.

Agfa-Gevaert is loss making, we can't compare the value of its earnings to the Switzerland market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Agfa-Gevaert, we can't assess if its growth is good value.


Price Based on Value of Assets

Agfa-Gevaert is good value based on assets compared to the Europe Healthcare Services industry average.


Next Steps

Future Growth

How is Agfa-Gevaert expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

-0.06%

Forecasted annual revenue growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Agfa-Gevaert's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.

Agfa-Gevaert's earnings are expected to grow significantly at over 20% yearly.

Agfa-Gevaert's revenues are expected to decrease over the next 1-3 years, this is below the Switzerland market average.

Agfa-Gevaert's earnings growth is expected to exceed the Switzerland market average.

Agfa-Gevaert's earnings growth is expected to exceed the low risk savings rate of 3.3%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Agfa-Gevaert will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Agfa-Gevaert performed over the past 5 years?

-27.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Agfa-Gevaert does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Agfa-Gevaert's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Agfa-Gevaert's 1-year growth to the Europe Healthcare Services industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Agfa-Gevaert has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Agfa-Gevaert has efficiently used its assets last year compared to the Europe Healthcare Services industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Agfa-Gevaert improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Agfa-Gevaert's financial position?


Financial Position Analysis

Agfa-Gevaert is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Agfa-Gevaert's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Agfa-Gevaert's level of debt (114.5%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (90.6% vs 114.5% today).

Operating cash flow is negative therefore debt is not well covered.

Agfa-Gevaert is making a loss, therefore interest payments are not well covered by earnings.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 3.8x debt.


Next Steps

Dividend

What is Agfa-Gevaert's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Agfa-Gevaert's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Agfa-Gevaert's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Agfa-Gevaert has not reported any payouts.

Unable to verify if Agfa-Gevaert's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Agfa-Gevaert has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Agfa-Gevaert's salary, the management and board of directors tenure and is there insider trading?

10.9yrs

Average management tenure


CEO

Christian Reinaudo (65yo)

9.3yrs

Tenure

€4,815,879

Compensation

Mr. Christian Reinaudo has been Chairman at Biocartis Group NV since May 2018. He has been the Chief Executive Officer and Executive Director at Agfa-Gevaert Limited since May 1, 2010 and 2010 respectively ...


CEO Compensation Analysis

Christian's remuneration is higher than average for companies of similar size in Switzerland.

Christian's compensation has increased whilst company is loss making.


Management Age and Tenure

10.9yrs

Average Tenure

55yo

Average Age

The average tenure for the Agfa-Gevaert management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

1.3yrs

Average Tenure

60yo

Average Age

The average tenure for the Agfa-Gevaert board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Christian Reinaudo (65yo)

    CEO, President & Executive Director

    • Tenure: 9.3yrs
    • Compensation: €4.82m
  • Stefaan Vanhooren (55yo)

    President of Agfa Graphics

    • Tenure: 15.6yrs
  • - Boyer

    Executive Vice President

    • Tenure: 0.0yrs
  • Luc Delagaye (59yo)

    President of Agfa Materials

    • Tenure: 11.3yrs
  • Luc Thijs (54yo)

    President of Agfa Healthcare

    • Tenure: 0.0yrs
  • Dirk De Man

    Chief Financial Officer

    • Tenure: 1.3yrs
  • Wilfried Van Lishout (55yo)

    Compliance Officer & Company Secretary

    • Tenure: 0.0yrs
  • Viviane Dictus

    Director of Corporate Communications

    • Tenure: 10.9yrs

Board Members

  • Jo Cornu (75yo)

    Independent Director

    • Tenure: 17.6yrs
    • Compensation: €70.00k
  • Christian Reinaudo (65yo)

    CEO, President & Executive Director

    • Tenure: 9.3yrs
    • Compensation: €4.82m
  • Hilde Laga (63yo)

    Independent Director

    • Tenure: 4.3yrs
    • Compensation: €70.00k
  • Helen Routh (57yo)

    Independent Director

    • Tenure: 0.3yrs
  • Klaus Röhrig (42yo)

    Chairman of the Board

    • Tenure: 0.3yrs
    • Compensation: €25.00k
  • Mark Pensaert (55yo)

    Independent Director

    • Tenure: 1.3yrs
    • Compensation: €75.00k
  • Frank Aranzana

    Director

    • Tenure: 0.3yrs

Company Information

Agfa-Gevaert NV's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Agfa-Gevaert NV
  • Ticker: AGFB
  • Exchange: SWX
  • Founded: 1867
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: €553.579m
  • Listing Market Cap: €602.881m
  • Shares outstanding: 167.75m
  • Website: https://www.agfa.com

Number of Employees


Location

  • Agfa-Gevaert NV
  • Septestraat 27
  • Mortsel
  • Antwerp
  • 2640
  • Belgium

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGFBENXTBR (Euronext Brussels)YesOrdinary SharesBEEURJun 1999
AGEDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 1999
0MFULSE (London Stock Exchange)YesOrdinary SharesGBEURJun 1999
AGFBBBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJun 1999
AGFBSWX (SIX Swiss Exchange)YesOrdinary SharesCHCHFJun 1999
AFGV.YOTCPK (Pink Sheets LLC)ADRUSUSDOct 2008

Biography

Agfa-Gevaert NV develops, produces, and distributes various analog and digital imaging systems, and IT solutions worldwide. The company operates through three segments: Agfa Graphics, Agfa HealthCare, and  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/24 22:11
End of Day Share Price2019/06/14 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.